Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882306 | 0.82 | KDM4E (0.48) | KDM4EPTGS1ALDH1A1KMT2AMEN1 | |
| SCHEMBL28047870 | 0.82 | CYP11B2 (0.44) | KDM4ENTRK1 | |
| SCHEMBL28260479 | 0.81 | KDM4E (0.47) | KDM4ESMN1; SMN2MAPTPTGS1CYP2C9 | |
| SCHEMBL598084 | 0.81 | KDM4E (0.50) | KDM4EPOLBNTRK1CYP2C9 | |
| SCHEMBL4886599 | 0.81 | KDM4E (0.47) | KDM4EPOLBSMN1; SMN2MAPTPTGS1 | |
| SCHEMBL24303668 | 0.81 | KDM4E (0.47) | KDM4EPOLBSMN1; SMN2MAPTNTRK1 | |
| SCHEMBL4854437 | 0.81 | KDM4E (0.47) | KDM4ESMN1; SMN2MAPTPTGS1CYP2C9 | |
| SCHEMBL4886275 | 0.80 | POLB (0.43) | KDM4EPOLBSMN1; SMN2NTRK1ALDH1A1 | |
| SCHEMBL13492177 | 0.80 | POLB (0.52) | KDM4EPOLBSMN1; SMN2CYP2C9ALDH1A1 | |
| SCHEMBL16217007 | 0.80 | POLB (0.52) | KDM4EPOLBSMN1; SMN2MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3348558-A1 | COMPOSITIONS COMPRISING FUSED IMIDAZOLE DERIVATIVES USEFUL AS IDO INHIBITORS | Newlink Genetics Corporation (US) | 2018-07-18 | — | — | EP | claimed |
| EP-3018132-A1 | FUSED IMIDAZOLE DERIVATIVES USEFUL AS IDO INHIBITORS | Newlink Genetics Corporation (US) | 2016-05-11 | — | — | EP | claimed |
| EP-2697227-B1 | FUSED IMIDAZOLE DERIVATIVES USEFUL AS IDO INHIBITORS | NEWLINK GENETICS CORP (US) | 2016-02-03 | — | — | EP | claimed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| CN-118271331-A | Gelsemin derivatives, synthesis method and application thereof in inhibiting tumor cell proliferation | 赣江中药创新中心 | 2024-07-02 | — | — | CN | disclosed |
| WO-2024134514-A1 | NOVEL COMPOUND AS RON INHIBITOR | 주식회사 엘지화학 | 2024-06-27 | — | — | WO | disclosed |
| WO-2024134517-A1 | NOVEL COMPOUND AS RON INHIBITOR | 주식회사 엘지화학 | 2024-06-27 | — | — | WO | disclosed |
| WO-2024134516-A1 | NOVEL COMPOUND AS RON INHIBITOR | 주식회사 엘지화학 | 2024-06-27 | — | — | WO | disclosed |
| WO-2024134515-A1 | NOVEL COMPOUND AS RON INHIBITOR | 주식회사 엘지화학 | 2024-06-27 | — | — | WO | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-9204647-B2 | Pyrazole compounds for controlling invertebrate pests | BASF SE (DE) | 2015-12-08 | — | — | US | disclosed |
| US-20140068820-A1 | Pyrazole Compounds for Controlling Invertebrate Pests | BASF SE (DE) | 2014-03-06 | — | — | US | disclosed |
| US-20140066625-A1 | Fused Imidazole Derivatives Useful as IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-03-06 | — | — | US | disclosed |
| US-7338956-B2 | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-04 | — | — | US | disclosed |
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20060217448-A1 | e.g. 4-benzyl-N-[2-(2-chlorophenyl)ethyl]-4,7,9-triazabicyclo[4.4.0]deca-7,9,11-triene-10-carboxamide; antiinflammatory and analgesic agent; rheumatoid arthritis, osteoarthritis, Parkinson's disease, uveitis, asthma, cardiovascular conditions, myocardial infarction | RENOVIS, INC. | 2006-09-28 | — | — | US | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885POLB 2574/4885SMN1; SMN2 3714/4885 |
| US-20060217448-A1 | e.g. 4-benzyl-N-[2-(2-chlorophenyl)ethyl]-4,7,9-triazabicyclo[4.4.0]deca-7,9,11-triene-10-carboxamide; antiinflammatory and analgesic agent; rheumatoid arthritis, osteoarthritis, Parkinson's disease, uveitis, asthma, cardiovascular conditions, myocardial infarction | PARK7, UACA, PTGER4 | KDM4E 2655/4885POLB 1746/4885SMN1; SMN2 1922/4885 |
| US-20140068820-A1 | Pyrazole Compounds for Controlling Invertebrate Pests | GRIN2A, PRXL2A, GRIN3A | KDM4E 3274/4885POLB 4040/4885SMN1; SMN2 2341/4885 |
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | KDM4E 4128/4885POLB 3676/4885SMN1; SMN2 4369/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | KDM4E 2869/4885POLB 4035/4885SMN1; SMN2 599/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885POLB 2574/4885SMN1; SMN2 3714/4885 |
| US-20140066625-A1 | Fused Imidazole Derivatives Useful as IDO Inhibitors | IDO1, IDO2, INMT | KDM4E 387/4885POLB 3519/4885SMN1; SMN2 4647/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885POLB 2574/4885SMN1; SMN2 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.